Presentation is loading. Please wait.

Presentation is loading. Please wait.

“Molecular Pathology past present & future” Thomas Kerr Principal Healthcare Scientist Molecular Pathology Pathology Department Southern General Hospital.

Similar presentations


Presentation on theme: "“Molecular Pathology past present & future” Thomas Kerr Principal Healthcare Scientist Molecular Pathology Pathology Department Southern General Hospital."— Presentation transcript:

1 “Molecular Pathology past present & future” Thomas Kerr Principal Healthcare Scientist Molecular Pathology Pathology Department Southern General Hospital

2 “Molecular Pathology past present & future” Thomas Kerr Principal Healthcare Scientist Molecular Diagnostics Genetics Southern General Hospital

3 Molecular Pathology ? The discipline involved in diagnostic, prognostic and predictive testing on samples (usually tumour) removed from the patient in the course of investigation and treatment of disease.

4

5

6

7

8 Laboratory Facility

9

10 Molecular pathology 1988: Maura Farquharson 1992 MSc project ISH based J Clin. Path 1996; “Immunoglobulin light chain mRNA detected by in situ hybridisation in diagnostic fine needle aspiration cytology specimens” First diagnostic molecular pathology technique Kappa & Lambda ISH

11 B & T cell lymphoma H&E morphology ICC ISH kappa, lambda & EBV FISH PCR

12 Lambda ICC

13 Lambda ISH

14 IgH clonality by Ceq8000

15 TCRgamma clonality by CEQ8000

16 TCRgamma polyclonal

17 Institute of neurological Science

18 GRI molecular pathology HER2 ICC & FISH Sarcoma FISH & RT-PCR Lymphoma FISH

19

20 Resection and Gliadel wafers No other post-op Rx

21 1p186 1p226 Normal Tumour Normal Tumour

22 19q112 Normal Tumour 19q219 Normal Tumour

23 N040300

24 valuable for patient counselling useful in deciding intensity of treatment can be used clinically to select patients likely to benefit from adjuvant temazolomide treatment. can potentially save half of patients from receiving chemotherapy. MGMT promoter status – clinical relevance

25 Methylated M U N040300

26 Predictive & Prognostic markers in Neuro-oncology Molecular assays introduced to aid typing & grading of gliomas Improved understanding of these tumours at molecular level Especially presence/absence of combined 1p19q loss in oligodendroglial tumours, MGMT promoter gene methylation in glioblastoma, EGFR amplification in grade III astrocytic tumours & glioblastoma & IDH mutation analysis Now being used to tailor treatment decisions in patients, current therapy combination of surgery, radiotherapy & chemotherapy

27 49F frontal 60F temp/parietal 1p 19q 1p 19q

28 Molecular Haematology 2008 Microsatellites for Chimaerism testing in post- BMT patients BCRABL (t9;22) PMLRARA (t15;17) in AML AML/ETO (t8;21) in AML Chromosome 16 inversion in AML JAK 2 status in myeloproliferative diseases FLT3 mutations

29 Chimaerism

30 Fiona M Reid April 2011 Purpose of Chimaerism testing post BMT To detect an identifiable difference between a patient and their donor Ability to measure the proportion of donor present in the blood or bone marrow post transplant

31 Identification of chimaerism Microsatellites: Short Tandem Repeats Prepare DNA from blood or marrow PCR A number of primer sets in use Must identify an “informative “ set of primers

32 Preparation of DNA: the EZ1

33 Chimaerism on Lymphoid/Myeloid split Blood sample post BMT Use CD3 to enrich for Lymphocyte fraction Use CD15 to enrich for Myeloid fraction

34 Automacs Proseparator

35 Fiona M Reid April 2011 Microsatellites Full donor Chimaerism

36 Fiona M Reid April 2011 Microsatellites Mixed Chimaerism

37 Recommendations from the molecular pathology review group on the future of molecular pathology testing in Scotland. (2010) The Calman review of genetics in relation to healthcare in Scotland Better health better care action plan Better cancer care action plan Clinical trials SPAN & Scottish cancer group networked approach to HER2 FISH testing

38 Conclusions & recommendations A molecular pathology service should be developed and run as a NSD supported consortium, mirroring the Scottish genetics laboratory consortium for diagnosis of constitutional genetic abnormalities. To ensure the stability of the services, equity of access and service development Linked to the Scottish cancer taskforce, cancer networks and Scottish medicines consortium so that there is early coordinated planning for new testing.

39 Laboratory Facility

40 Targeted therapies Therapeutic monoclonal antibodies Small molecules

41 Therapeutic monoclonal antibodies Target specific antigens on proteins- extracellular growth factors eg transmembrane receptors Monoclonal antibodies end with the stem “mab” e.g. cetuximab which targets EGFR

42 Small molecules Penetrate the cell membrane to interact with targets inside a cell Interfere with the enzymatic activity of the target protein End with the stem “ib”, the agent has inhibitory properties e.g. imatinib in CML

43 Cost Targeted therapies £20000 per patient per year Molecular test EGFR £50

44 = Different outcomes Different outcomes Current Treatment is the Same for Most Patients Outcomes can vary widely = Patients Treatment + Disease + Different treatment outcomes affect patients’ safety, survival and quality of life

45 The Alternative: Personalized Healthcare (PHC) Tailors treatment to the patient Molecular diagnostic testing can stratify patients according to their specific genetic makeup and/or the nature of their disease or condition This approach improves drug safety, may increase patient survival, and may improve quality of life

46 Personalized Healthcare Provides benefits for all stakeholders Improved benefit to risk ratio Patient Efficient use of healthcare budgets Payer Informed treatment decisions Healthcare provider

47 Near to mid-term genomics and oncology portfolio Platform consolidation; Pharma driven focus on oncology RMD is committed to expanding the oncology menu in order to remain competitive in the oncology IVD market.

48 Biomarker Test Disease Therapeutic Class Drug(s) cobas ® BRAF Mutation Test Metastatic Melanoma BRAF Inhibitors RG7204 (PLX 4032), Zelboraf cobas ® KRAS Mutation Test Colorectal Cancer Anti-EGFR Monoclonal Antibodies (mAb) Anti-EGFR mAb Therapies, cetuximab, panitumumab cobas ® EGFR Mutation Test Non-Small Cell Lung Cancer (NSCLC) Anti-EGFR Tyrosine Kinase Inhibitors Erlotinib, Gefitinib Current Cobas ® Oncology Portfolio Clinically validated biomarker tests on one platform

49 cobas® 4800 Oncology Tests Workflow Overview

50 Melanoma Progression Melanoma is the most aggressive form of skin cancer originating in the melanocytes. 197,000 people worldwide are diagnosed with melanoma each year 50

51 BRAF Mutation Test Designed to identify metastatic melanoma patients who may benefit from BRAF inhibitors The cobas ® 4800 BRAF V600 Mutation Test –Is designed to determine mutation status of the BRAF gene –Is the companion diagnostic used in the clinical trials for RG7204 (also known as PLX4032), an oral inhibitor of mutated BRAF co-developed by Roche Pharmaceuticals and Plexxikon. BRIM2 +3 clinical trials (>2,000 patients)~ Roche kit is the ONLY clinically validated kit. –RG7204 has shown strong clinical activity in metastatic melanomas harboring the BRAF V600E mutation; clinical data suggests that patients with wild-type BRAF do not respond or respond adversely.

52

53 Colorectal Cancer Progression Incidence in the UK: ~70 cases per 100,000 >95% of colorectal cancers arise from the glandular epithelium that lines the gut (adenocarcinomas)

54 cobas ® KRAS Mutation Test Designed to help identify colorectal patients who are unlikely to benefit from anti-EGFR mAb therapies cobas ® KRAS Mutation Test: Is designed to determine mutation status of the KRAS oncogene Colorectal cancer tumors with KRAS mutations are unresponsive to anti-EGFR therapies 1 When combined with other clinical data, this information will help physicians identify colorectal cancer patients who may not benefit from anti-EGFR mAb therapies 1. Amado et al. J Clin Oncol 2009;26:1626  1634

55 cobas ® KRAS Mutation Test Designed to help identify colorectal patients who are unlikely to benefit from anti-EGFR mAb therapies cobas ® KRAS Mutation Test: Is designed to determine mutation status of the KRAS oncogene Colorectal cancer tumors with KRAS mutations are unresponsive to anti-EGFR therapies 1 When combined with other clinical data, this information will help physicians identify colorectal cancer patients who may not benefit from anti-EGFR mAb therapies 1. Amado et al. J Clin Oncol 2009;26:1626 

56 Non-small cell lung cancer Overview Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related deaths worldwide: ~106,000 new cases of advanced lung cancer per year in the UK, France, Spain, Italy and Germany combined. NSCLC is the most prevalent and accounts for approximately 85% of all cases. Prognosis for patients with NSCLC is poor with a 5-year survival rate of only 15%.

57 Non-small Cell Lung Cancer Therapy Options - Overview Treatment of cancer is guided by disease stage: early stages: primary treatment is surgical resection locally advanced or metastatic disease: platinum-based chemotherapy targeted therapy anti-EGFR (cetuximab, panitumumab) tyrosine kinase inhibitors: erlotinib (Roche Tarceva ® and gefitinib (AstraZenaca Iressa ® ) anti-VEGF (Roche Avastin ® )

58 Non-small Cell Lung Cancer Role of EGFR EGFR is a receptor tyrosine kinase located on the cell surface of epithelial cells. EGFR is linked to several signaling pathways including the RAS/MAPK pathway and the PI3K/Akt pathway. In normal cells, these pathways are tightly regulated and are activated only when a specific ligand (such EGF) binds to the receptor. In cancer cells, EGFR gene mutations activate the kinase in the absence of a ligand leading to abnormal cell proliferation and tumor formation. 58

59 cobas ® EGFR Mutation Test Designed to help identify NSCLC patients who may benefit from anti-EGFR TKI therapy cobas ® EGFR Mutation Test: Is designed to detect mutations in the EGFR gene in NSCLC tumor tissue Test results will help physicians identify NSCLC patients who may benefit from anti- EGFR tyrosine kinase inhibitor therapy

60 Next Generation Sequencing High throughput, low cost (?) sequencing technology Human Genome Project started in 1990 and took 13 years to complete It was an international collaboration which cost $3 billion and used traditional Sanger sequencing Today you could sequencing the human genome in ~month using NGS Target is the $1000 genome

61 Next Generation Sequencing Many NGS techniques, chemistries and instruments now available Personal genome machines (PGMs) are affordable bench-top instruments e.g. Ion Torrent NGS allows you to look at many genes or regions of the genome, from many patients, simultaneously NGS has multiple applications and will replace many of the molecular tests currently available in the lab

62 Ion Torrent

63 The present: small (and a little odd looking)

64 Ion Torrent Personal Genome Machine Bench-top NGS instrument from Life Technologies. Purchase the Comprehensive Cancer Panel from Life Technologies which targets exons within 409 oncogenes and tumour suppressor genes. Requires 10ng of input DNA from FFPE tissue. Produces amplicons of between bp and has 16,000 primers in 4 tubes. From DNA extraction to results is less than 24 hours, and the laboratory process is almost fully automated

65 The future: bigger and better What is bigger and better? Bigger is looking at more genes, better is improving the patients diagnosis and treatment in doing so How do we do bigger and better? By sequencing the entire exome, every single base of each coding exon in the genome In the future it will be cheaper and easier to sequence the whole exome for every patient

66 NGS: the future

67

68 Life Technologies claim the Ion proton will sequence the entire human genome in 8 hours

69

70 Acknowledgements Maura Farquharson Willie Stewart Molecular pathology team SGH Nicola Williams, Jane Duncan, Rachel Ellis Aly Grant (Roche)

71 Information CRUK stratified medicine Life technologies ion torrent


Download ppt "“Molecular Pathology past present & future” Thomas Kerr Principal Healthcare Scientist Molecular Pathology Pathology Department Southern General Hospital."

Similar presentations


Ads by Google